Journal of ethnopharmacology · 2026
Assessment of Xiao'er Xiexieting Keli-induced toxicity in juvenile rats.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Junxiu, Zhu Lin, Lu Xiaojing, Fu Weidong, Rao Tingfei, Zhang Lili, Wang Jiahong, Chen Lingfang, Tian Ruiyu, Zhu Haojie, Ge Lingyun, Wu Lei, Lv Wanqiang, Huang Wenhai, Huang Linfeng, Song Yisheng
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Sufficient safety data on juvenile development is not available for Xiao'er Xiexieting Keli (XXTK), a Chinese herbal formula for pediatric diarrhea.
AIM OF THE STUDY: Considering the challenges associated with clinical trials of XXTK, this study was aimed at evaluating its toxicity in juvenile rats to obtain a basis for assessing its safety and dosage in children.
MATERIALS AND METHODS: In acute toxicity study (Study 1), postnatal day (PND) 24 rats were orally administered 253.13 g/kg XXTK and observed over 14 days. In subacute toxicity study (Study 2), PND21 rats were administered 1.74, 8.71, or 32.66 g/kg XXTK daily for six consecutive weeks and allowed to recover for 4 weeks. Clinical signs, body weight, food intake, and timing of vaginal opening and preputial separation were recorded during the dosing period. Hematological, serum biochemical, and histopathological examinations, Irwin's test, and assessment of growth hormone levels, skeletal development, and immune-related indicators were performed mid-administration, and at culmination of dosing and recovery. Urinalysis, ophthalmological assessment, and Morris water maze test were conducted at the end of dosing and recovery periods.
RESULTS: No deaths or significant findings occurred in Study 1; maximum tolerated dose was 253.13 g/kg. In Study 2, all changes were reversible, mild, and without toxicological significance. The no-observed-adverse-effect level was 32.66 g/kg/day.
CONCLUSION: XXTK demonstrated a favorable toxicological safety profile in juvenile rats, supporting its potential for extended clinical use in children. Further evaluation of child development-related indicators and validation in pediatric clinical cohorts are recommended.
AIM OF THE STUDY: Considering the challenges associated with clinical trials of XXTK, this study was aimed at evaluating its toxicity in juvenile rats to obtain a basis for assessing its safety and dosage in children.
MATERIALS AND METHODS: In acute toxicity study (Study 1), postnatal day (PND) 24 rats were orally administered 253.13 g/kg XXTK and observed over 14 days. In subacute toxicity study (Study 2), PND21 rats were administered 1.74, 8.71, or 32.66 g/kg XXTK daily for six consecutive weeks and allowed to recover for 4 weeks. Clinical signs, body weight, food intake, and timing of vaginal opening and preputial separation were recorded during the dosing period. Hematological, serum biochemical, and histopathological examinations, Irwin's test, and assessment of growth hormone levels, skeletal development, and immune-related indicators were performed mid-administration, and at culmination of dosing and recovery. Urinalysis, ophthalmological assessment, and Morris water maze test were conducted at the end of dosing and recovery periods.
RESULTS: No deaths or significant findings occurred in Study 1; maximum tolerated dose was 253.13 g/kg. In Study 2, all changes were reversible, mild, and without toxicological significance. The no-observed-adverse-effect level was 32.66 g/kg/day.
CONCLUSION: XXTK demonstrated a favorable toxicological safety profile in juvenile rats, supporting its potential for extended clinical use in children. Further evaluation of child development-related indicators and validation in pediatric clinical cohorts are recommended.